Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform |
| |
| Institution: | 1. CIQUP-IMS, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal;2. Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal;3. UCIBIO – Applied Molecular Biosciences Unit, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira nº 228, 4050-313 Porto, Portugal;1. Duke-NUS Medical School, 8 College Road, 169857, Singapore;2. Department of Neurology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, 308433, Singapore;3. Department of Diagnostic Radiology, Singapore General Hospital, 31 Third Hospital Ave, 168753, Singapore;1. The M.O.E. Key Laboratory of Laboratory Medical Diagnostics, The College of Laboratory Medicine, Chongqing Medical University, #1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China;2. University of Electronic Science and Technology of China, Chengdu, China;3. Department of Clinical Laboratory, Fuling Central Hospital of Chongqing City, Chongqing, 408008, China;4. School of Sensing Science and Engineering, Shanghai Jiao Tong University, Shanghai, China;5. Sichuan Provincial Key Laboratory for Human Disease Gene Study, Department of Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People''s Hospital, University of Electronic Science and Technology, Chengdu, 610072, China;1. Univ. Coimbra, Department of Pharmaceutical Technology, Faculty of Pharmacy, Azinhaga de Santa Comba, Pólo III - Pólo das Ciências da Saúde, 3000-548, Coimbra, Portugal;2. Univ. Coimbra, CIEPQPF, FFUC, Laboratory of Pharmaceutical Chemistry, Azinhaga de Santa Comba, Pólo III - Pólo das Ciências da Saúde, 3000-548, Coimbra, Portugal;3. Univ. Coimbra, REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, Azinhaga de Santa Comba, Pólo III - Pólo das Ciências da Saúde, 3000-548, Coimbra, Portugal;1. Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Department of Life Sciences and Medicine, Northwest University, Xi''an, 710069, China;2. Shaanxi Key Laboratory for Carbon Neutral Technology, China;1. Department of Mechanical Engineering and Mechanics, Drexel University, Philadelphia, PA 19104, USA;2. Department of Mechanical Engineering, Tsinghua University, Beijing 100084, China;3. Biomanufacturing and Rapid Forming Technology Key Laboratory of Beijing, Tsinghua University, Beijing 100084, China;4. “Biomanufacturing and Engineering Living Systems” Innovation International Talents Base (111 Base), Tsinghua University, Beijing 100084, China |
| |
| Abstract: | The discovery of effective drugs for the treatment of neurodegenerative disorders (NDs) is a deadlock. Due to their complex etiology and high heterogeneity, progresses in the development of novel NDs therapies have been slow, raising social/economic and medical concerns. Nanotechnology and nanomedicine evolved exponentially in recent years and presented a panoply of tools projected to improve diagnosis and treatment. Drug-loaded nanosystems, particularly nanoparticles (NPs), were successfully used to address numerous drug glitches, such as efficacy, bioavailability and safety. Polymeric nanoparticles (PNPs), mainly based on polylactic-co-glycolic acid (PLGA), have been already validated and approved for the treatment of cancer, neurologic dysfunctions and hormonal-related diseases. Despite promising no PNPs-based therapy for neurodegenerative disorders is available up to date. To stimulate the research in the area the studies performed so far with polylactic-co-glycolic acid (PLGA) nanoparticles as well as the techniques aimed to improve PNPs BBB permeability and drug targeting were revised. Bearing in mind NDs pharmacological therapy landscape huge efforts must be done in finding new therapeutic solutions along with the translation of the most promising results to the clinic, which hopefully will converge in the development of effective drugs in a foreseeable future. |
| |
| Keywords: | Neurodegenerative diseases Blood-brain barrier Brain targeting Drug delivery Poly(lactide-co-glycolide) acid nanoparticles |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
